LifeVantage — First Quarter Fiscal 2027 Earnings Summary

Financial Performance:

• Revenue was $37.1 million, a 22.0% decrease from $47.6 million in the prior year period, including a $0.4 million negative impact from foreign currency.
• Net loss per diluted share was $0.02, compared to net income per diluted share of $0.17 a year ago.
• Adjusted earnings per diluted share was $0.05, compared to $0.18 a year ago.
• Adjusted EBITDA was $1.9 million, or 5.2% of revenue, compared to $3.9 million, or 8.2% of revenue, a year ago.
• Gross profit was $28.0 million (75.4% of revenue), down from $37.8 million (79.5% of revenue) in the prior year; adjusted non-GAAP gross profit was $29.0 million (78.2% of revenue).
• Operating loss was $0.1 million, compared to operating income of $2.3 million in the prior year period.
• Cash generated from operations was $0.5 million, compared to $2.3 million used in operations in the prior year period.
• Cash and cash equivalents were $13.7 million as of September 30, 2026, down from $14.9 million at June 30, 2026.
• There was no debt outstanding.

Business Segments and Product Lines:

• Revenue in the Americas decreased 22.2% to $29.0 million.
• Revenue in Asia/Pacific & Europe decreased 21.2% to $8.2 million, including a $0.4 million negative impact from foreign currency.
• The revenue decline was primarily driven by lower active accounts and lower sales of the MindBody GLP-1 System®.
• Sales of the LoveBiome product line, acquired in October 2025, partially offset declines.
• Total Active Accounts decreased to 98,000 from 121,000 a year ago, a 19.0% decline.
• Active Independent Consultants decreased to 40,000 from 48,000 a year ago, a 16.7% decline.
• Active Customers decreased to 58,000 from 73,000 a year ago, a 20.5% decline.

Other Key Points:

• The Company did not repurchase any shares of common stock during the quarter.
• As of September 30, 2026, $58.5 million remained under the $60 million share repurchase program.
• A $1.0 million allowance for inventory obsolescence related to the MindBody GLP-1 System® contributed to the decrease in gross profit margin.
• Commissions and incentives expense was $15.4 million (41.4% of revenue), down from $20.7 million (43.5% of revenue) in the prior year.
• Selling, general and administrative (SG&A) expense was $12.7 million (34.3% of revenue), up from $14.9 million (31.2% of revenue) in the prior year.